One Antibiotic Course Left Mouse Gut Bacteria Altered 46-Fold, Study Finds

If you've ever finished a round of antibiotics and felt like your gut never quite went back to normal, you're describing something researchers are now able to measure with real precision, and it looks like you may have been right longer than most doctors would guess. A new cross-study re-analysis pooled four separate, independently run mouse experiments and found the same pattern in every one: a common antibiotic called ceftriaxone doesn't just knock gut bacteria down temporarily, it restructures the whole community in ways that are still detectable months later. That kind of agreement across four unrelated labs is rare in microbiome research, and it's why this analysis, published in Frontiers in Cellular and Infection Microbiology, is worth paying attention to even though it was done in mice, not people.

Key takeaways

• Ceftriaxone (a widely used antibiotic, also used off-label in neuroscience labs to boost a brain protein called GLT-1) caused the bacterial family Enterococcaceae to expand 46.4-fold in treated mice, one of the largest, most statistically confident shifts reported.
• The disruption showed up consistently across four independent mouse datasets (roughly 452 animals total) reprocessed through the same standardized pipeline, a form of replication that's uncommon in microbiome studies.
• Gut bacterial diversity was still measurably different from controls beyond 98 days after exposure, meaning recovery was incomplete, not just delayed.
• This is a mouse-only re-analysis of existing data; the metabolic-function findings are computer-predicted from bacterial identity, not measured directly, and none of this has been confirmed in humans.

Ceftriaxone Triggered a 46-Fold Enterococcaceae Surge Across Four Mouse Cohorts

Ceftriaxone, a β-lactam antibiotic (a broad class that includes penicillin-related drugs), caused the bacterial family Enterococcaceae to balloon 46.4-fold relative to untreated mice, a change so statistically strong the researchers reported a q-value (a significance score adjusted for testing many bacteria at once) of 1.5 x 10⁻⁴³, effectively as close to certain as microbiome statistics get. Zooming in further, the genus Enterococcus specifically rose 21-fold. This wasn't an isolated blip: the team, led by Andrew Winters and colleagues at Wayne State University School of Medicine, reprocessed four separate publicly available mouse datasets, from four different research groups, through one standardized bioinformatic pipeline and found the same directional shifts everywhere they looked. Alongside Enterococcaceae, several other bacterial families rose 4 to 31-fold in treated mice, while typically beneficial groups like Bacteroidaceae dropped several-fold. Every measure of bacterial diversity the researchers tracked (Chao1, Shannon, and Inverse Simpson, three standard ways of scoring how many different species are present and how evenly balanced they are) fell significantly in treated mice, with the gap only partially closing over time. You can read the full study on the Frontiers in Cellular and Infection Microbiology site.

Why This Matters If You're Untangling Gut Symptoms After Antibiotics

Anyone researching their own gut health after a course of antibiotics, especially people managing IBS, IBD, eczema, or mood symptoms they suspect are gut-linked, should care about this because it puts real numbers behind a pattern many patients report anecdotally: things don't just "reset" once the prescription ends. Ceftriaxone specifically is worth knowing about for another reason. It's used clinically to treat serious bacterial infections like meningitis and gonorrhea, but it's also a workhorse drug in neuroscience labs, where researchers give it to lab animals specifically because it boosts a glutamate transporter called GLT-1, a protein that helps clear excess glutamate (the brain's main excitatory signaling chemical) and is studied for its role in addiction, memory, and neurodegenerative disease. A related peer-reviewed paper has raised the possibility that some of ceftriaxone's brain effects in these experiments might be partly mediated through the gut, not purely direct action in the brain, which would be a significant wrinkle for a drug so routinely used in neuroscience research.

Four Independent Datasets, One Standardized Pipeline

The credibility of this analysis rests on its method: rather than running a new experiment, the researchers combined four already-published, independent mouse studies (Chakraborty 2018, Gregoire 2021, Hong 2024, and Winters 2024) representing different mouse strains, sexes, dosing schedules, and follow-up windows ranging from a few days to well over a year, and reanalyzed all of them together using the same bioinformatic tools: DADA2 for sequence processing, phyloseq and Maaslin2 for statistical comparisons, PICRUSt2 for predicting bacterial function, and Bayesian modeling to handle the zero-inflated nature of microbiome count data. Combined, the four datasets covered roughly 452 mice. Finding the same core pattern, reduced diversity, an Enterococcaceae bloom, incomplete recovery, across studies that were never designed to be compared to each other is a stronger form of evidence than any single study alone, because it rules out one lab's mice, diet, or sequencing quirks as the explanation.

What This Means If You've Taken Ceftriaxone or Similar Antibiotics

This study does not test people, and it does not tell you what to do about your own gut. What it does offer is a clearer picture of the biological plausibility behind something a lot of patients already suspect: that a single antibiotic course can leave a gut community altered well past the point where symptoms like bloating or altered bowel habits might have already faded from memory. If you've noticed digestive changes that started around an antibiotic course and never fully resolved, that's a reasonable thing to bring up with a doctor or gastroenterologist, not as proof of anything (this study can't establish that), but as useful context for the conversation. The study does not establish that any particular probiotic, diet, or supplement reverses these changes in mice or in people, so treat claims that promise to "restore" your microbiome after antibiotics with real skepticism until there's direct evidence behind them.

What This Study Can't Tell Us Yet

The biggest limitation, one the authors themselves flag directly, is that the metabolic and functional findings, like predicted shifts in amino acid and biotin-related pathways, come from PICRUSt2, a tool that infers likely bacterial functions from which species are present rather than measuring actual metabolites or gene activity in the gut. That's a computational estimate, not a direct measurement, and the authors are explicit that it needs confirmation with real metabolomics data. The individual dataset sizes were also, in the authors' own words, "generally insufficient" to cleanly separate out effects of mouse strain, sex, and antibiotic dose from each other, even though the combined sample across all four studies was large. One of the four source datasets was further complicated by mice also receiving a bacterial pathogen gavage as part of its original experiment, an unrelated confound the re-analysis authors had to account for. And, critically, this is a secondary re-analysis of existing public data using mice, not new wet-lab experiments and not a human study; nothing here has been shown to happen the same way in people. A separate NIH-funded pilot study in mice found similarly incomplete bacterial recovery after antibiotics, with a majority of affected bacterial types still absent months later, suggesting this pattern of partial, lingering disruption may not be unique to ceftriaxone.

What Comes Next: Metabolomics and Human Studies

The authors point toward direct metabolomics work (chemically measuring what compounds are actually present in the gut, rather than predicting them from bacterial DNA) as the natural next step to confirm whether the PICRUSt2-predicted functional shifts are real. Given ceftriaxone's heavy use in neuroscience research specifically to manipulate GLT-1, the authors also argue that labs using this drug should be accounting for gut-microbiome effects as a potential confound in their own behavioral results, not treating it as a clean, brain-only manipulation. No timeline for follow-up work is given in the study, and there is no indication yet of a planned human trial.

Common Questions

Is ceftriaxone a commonly prescribed antibiotic? Yes. It's a widely used injectable antibiotic for serious bacterial infections including certain types of pneumonia, meningitis, and gonorrhea, and it's separately used in animal research specifically for its effect on a brain protein called GLT-1.

Does this mean antibiotics permanently damage gut bacteria? This study doesn't establish permanence. It shows partial recovery was still happening but incomplete beyond 98 days in mice, which is different from proving the changes never resolve at all; longer follow-up and human data would be needed to answer that.

What is PICRUSt2, and can the metabolic findings in this study be trusted the same way as the bacterial counts? PICRUSt2 is a bioinformatic tool that predicts likely bacterial functions based on which species are present, rather than directly measuring chemical activity in the gut. The bacterial population shifts in this study were directly measured and are well-supported; the functional/metabolic predictions are a computational estimate the authors themselves say still needs confirmation.

Should I take a probiotic after finishing antibiotics based on this research? This study didn't test any intervention, probiotic or otherwise, so it offers no evidence either way. Any decision about probiotics or supplements after antibiotics is worth discussing with a doctor rather than basing on this animal re-analysis.

References

1. Andrew D. Winters, Esha Rudagi, Orena Koka, Mariana Angoa-Perez (2026). Persistent gut microbiota dysbiosis and metabolic remodeling after ceftriaxone exposure in mice: a cross-study re-analysis. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1822390
2. Andrew D. Winters, Dina M. Francescutti, David J. Kracht, Donald M. Kuhn, Mariana Angoa-Perez (2024). The Effects of Ceftriaxone on Glutamate Transporter Expression and the Gut Microbiome: Implications for a Role of Antibiotic-Induced Dysbiosis in Mediating Drug Seeking and Relapse. Gut Microbes Reports. https://doi.org/10.1080/29933935.2024.2393727
3. Daniel Laubitz, Katri Typpo, Monica Midura-Kiela, et al. (2021). Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study). Microorganisms. https://doi.org/10.3390/microorganisms9030647